Comparison of efficacy and safety of antiretroviral first-line therapy with phosphazideortdf
https://doi.org/10.22625/2072-6732-2018-10-4-37-41
Abstract
The aim of the study was to compare the efficacy and safety of ART regimens, which included TDF or PhAZT, in patients with HIV infection who had not received treatment previously.
Patients. The study included 85 adult patients with HIV infection. Group 1 consisted of 60 patients who received TDF/FTC + EFV. The second group included 25 patients who received PhAZT + 3TC + EFV. The study was not randomized, comparative, patient groups were similar in terms of the main indicators. The efficacy and safety of the treatment was assessed during the first 24 weeks of therapy.
Results. After 24 weeks of therapy, 74,5% of patients in Group 1 and 87,5% of patients in Group 2 had less than 50 copies/ml of HIV RNA (MITT analysis). The increase in the median CD4 + lymphocytes after 24 weeks of treatment was 143 and 135 cells/μl, respectively. Most of the AE (including all AE that caused change or cancellation of the treatment regimen) were associated with the use of EFV. In 22,4% of patients receiving TDF, transient proteinuria was noted, and in 17,2% – deviation of blood creatinine level deviation of mild severity. The safest drugs included PhAZT, FTC and 3TC. The most frequent AE associated with the use of PhAZT, there was a slight decrease in hemoglobin and red blood cell count.
Conclusion. The study conducted in the conditions close to real clinical practice showed that both first-line ART regimens, including TDF or Phosphazide in addition to 3TC (FTC) and EFV antiretroviral drugs, were highly effective and safe during the first 24 weeks of treatment. PhAZT is a drug of choice in the schemes of ART of the first line in the presence of contraindications to the prescription of TDF and/or ABC.
About the Authors
A. V. Kravchenko
Central Research Institute of Epidemiology” of The Federal Service on Customers’ Rights Protection and Human Well-being Surveillance
Russian Federation
Russian Federation
U. A. Kuimova
Central Research Institute of Epidemiology” of The Federal Service on Customers’ Rights Protection and Human Well-being Surveillance
Russian Federation
Russian Federation
O. S. Efremova
Central Research Institute of Epidemiology” of The Federal Service on Customers’ Rights Protection and Human Well-being Surveillance
Russian Federation
Russian Federation
E. S. Ivanova
Perm Regional Center for the Prevention and Control of AIDS and Infection Diseases, Perm
Russian Federation
Russian Federation
A. A. Popova
Central Research Institute of Epidemiology” of The Federal Service on Customers’ Rights Protection and Human Well-being Surveillance
Russian Federation
Russian Federation
References
1. PokrovskyV.V., YurinO.G., KravchenkoA.V., BelyaevaV.V., ErmakT. N., KanestriV. G., ShakhgildyanV. I., KozyrinaN.V.. Buravtsova E. V., Narsiya R. S., Khokhlova O. N., Pokrovskaya, V. A., Efremova O. S., Konnov V. V., Kuimova U. A., Popova A. A., Voronin E. E., Afonina L. Yu., Vasilyeva I. A., Zimina V. N. National guidelines for dispensary observation and treatment of patients with HIV-infection 2017. (The clinical Protocol). Epidemiology and infectious diseases. The actual issues.- 2017.-No. 6, the Application.- 1-80 p. (Rus.)
2. Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 9.0; October, 2017). EuropeanAIDS Clinical Society (http://www.europeanaidsclinicalsociety.org).
3. Kravchenko A. V., Galegov G. A., Kanestri V. G. // Monograph “PHOSPHAZIDE” // -M.: publishing house “MEDPRAKTIKA-M”, 2017, 208 p. (Rus.)
4. Ivanova E. S. Phosphazide and lamivudine as a nucleoside basis of the schemes of the first row of antiretroviral therapy for HIV infection. Epidemiology and infectious diseases, 2016, №4, p. 75-80. (Rus.)
5. Khokhlov A. F., Brovchenko V. B., Smirnov A. A. The Development and registration of a combined medicinal product for the treatment of HIV infections is based on nucleoside reverse transcriptase inhibitors (NRTIs) – phosphazide and lamivudine. Development and registration of medicines. 2016; 1 (14): 48-62 (Rus.).
6. Sizova N. V. Modestova I. O., Shakhov F. F., Koblevskaya N.V.,Klitsenko, O. A., Kravchenko A. V., Yurin O. G., Gusev D. A. Evaluation of the efficacy and safety of ART regimens containing low-dose phosphazide. Journal of Infectology, 2017, 9 (3), 61-66 (Rus.).
7. Kravchenko A. V., Orlova-Morozova E. A., SimonovaT.E., Kozyrev O. A., Nagimova F. I., Zakharova N. G., Ivanova E. S., Kuimova U. A., Efremova O. S., Sonin D. B., Chernova O. E., Tonkikh O. S., Yakovlev A. A., Kurina N.V. Pokrovsky V. V., Bychko V. V., Vostokova, N. V. Zozulya, O. V. Efficacy and safety of a new Russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with tenofovir/emtricitabine – a multicenter comparative study with efavirenz in patients with HIV infection who have not previously received treatment. Infectious diseases, 2017, 15 (3), 5-13 (Rus.).
Review
For citations:
Kravchenko A.V., Kuimova U.A., Efremova O.S., Ivanova E.S., Popova A.A. Comparison of efficacy and safety of antiretroviral first-line therapy with phosphazideortdf. Journal Infectology. 2018;10(4):37-41. (In Russ.) https://doi.org/10.22625/2072-6732-2018-10-4-37-41
Views:
1197
.png)
.png)
Email this article 